Notis-McConarty Edward’s Alnylam Pharmaceuticals ALNY Stock Holding History

Notis-McConarty Edward’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,386	Closed	-$229K	–	96
2016 Q3	$229K	Buy	+3,386	New	+$239K	0.16%	93
2016 Q2	–	Sell	-3,386	Closed	-$213K	–	95
2016 Q1	$213K	Buy	3,386 +50	+1%	+$3.32K	0.15%	95
2015 Q4	$314K	Buy	3,336 +50	+2%	+$4.64K	0.23%	83
2015 Q3	$263K	Sell	3,286 -50	-1%	-$5.55K	0.2%	87
2015 Q2	$400K	Hold	3,336	–	–	0.27%	78
2015 Q1	$348K	Sell	3,336 -250	-7%	-$25.3K	0.24%	86
2014 Q4	$348K	Sell	3,586 -25	-0.7%	-$2.32K	0.24%	87
2014 Q3	$282K	Hold	3,611	–	–	0.2%	92
2014 Q2	$228K	Buy	3,611 +500	+16%	+$29.7K	0.15%	98
2014 Q1	$208K	Sell	3,111 -3,111	-50%	-$241K	0.15%	98
2013 Q4	$399K	Buy	+6,222	New	+$371K	0.28%	78

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Notis-McConarty Edward's ALNY Position: Q4 2016 in Review

Notis-McConarty Edward sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 3,386 shares — an estimated $229K sold.

Notis-McConarty Edward first reported a position in ALNY in Q4 2013 and held it in 11 quarters. The position peaked at $400K in Q2 2015. 210 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Notis-McConarty Edward reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Notis-McConarty Edward sold 3,386 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $229K.
Notis-McConarty Edward first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 11 quarters.
Notis-McConarty Edward's Alnylam Pharmaceuticals position peaked at $400K in Q2 2015.
210 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Notis-McConarty Edward's 13F filing for Q4 2016, filed 14 Feb 2017.